易生活控股(00223.HK)延長配售最多1.5億股最後截止日期
格隆匯1月20日丨易生活控股(00223.HK)公吿,內容有關根據一般授權配售最多150,537,742股配售股份;根據就配售協議所訂立日期為2023年1月5日補充協議,最後截止日期已由2023年1月9日延長至2023年1月30日(或公司與配售代理可能協定較後日期)。
由於農曆新年假期將至而配售代理需要更多時間促成投資者認購配售股份,公司與配售代理於2023年1月20日訂立配售協議第二份補充協議,據此,訂約各方同意將最後截止日期由2023年1月30日進一步延長至2023年2月20日(或公司與配售代理可能協定較後日期)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.